Plasma protein binding of zomepirac sodium.
The plasma protein binding of zomepirac, a new nonnarcotic analgesic, was studied using equilibrium dialysis. Experiments were performed using human plasma and plasma from mice, rats, and rhesus monkeys, all species of pharmacological or toxicological interest. At concentrations approximating those achieved in vivo, the binding was fairly constant at 98-99% in all species except the rhesus monkey, where binding was decreased from 98 to approximately 96% at higher concentrations (greater then 50 microgram/ml). Zomepirac (10 microgram/ml) did not appear to displace or to be displaced by warfarin (10 microgram/ml) caused a concentration-dependent decrease in zomepirac (10 microgram/ml) binding. Zomepirac did not affect salicylate binding.